alofanib   Click here for help

GtoPdb Ligand ID: 11622

Synonyms: RPT-835 | RPT835
Compound class: Synthetic organic
Comment: Alofanib (RPT835) is an allosteric inhibitor of the receptor tyrosine kinase, fibroblast growth factor receptor 2 (FGFR2) [1-4]. It inhibits phosphorylation of FGF receptor substrate 2α (FRS2α), but does not block FGF2-FGFR2 binding. Alofanib inhibits angiogenesis and was developed for antitumour potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 147.88
Molecular weight 413.07
XLogP 4.21
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES [O-][N+](=O)c1cc(C)c(cc1NS(=O)(=O)c1cccc(c1)C(=O)O)c1cccnc1
Isomeric SMILES [O-][N+](=O)c1cc(C)c(cc1NS(=O)(=O)c1cccc(c1)C(=O)O)c1cccnc1
InChI InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)
InChI Key QUQGQIASFYWKAB-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Alofanib (RPT835) is in early phase evaluation for gastric cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04071184 Study of Alofanib in Patients With Metastatic Gastric Cancer Phase 1 Interventional Russian Pharmaceutical Technologies